Strategies & Technologies Driving Drug Discovery to Market
Contract Formulation Company Profile - Metrics, Inc.
March 3, 2009 4:11 am | Articles | CommentsMetrics is contract development and manufacturing organization that provides quality work to quality clients from quality people.
Contract Formulation Company Profile - CoreRx, Inc.
March 3, 2009 4:06 am | Articles | CommentsCoreRx, Inc. is a full service classical pharmaceutical development and consultation organization dedicated to bringing investigational, new, and abbreviated drug applications to the market.
Contract Formulation Company Profile - Cirrus Pharmaceuticals
March 3, 2009 4:00 am | Articles | CommentsCirrus Pharmaceuticals, Inc. is a Contract Research Organization specializing in Strategic Product Development.
Contract Formulation Company Profile - BioConvergence LLC
March 3, 2009 3:53 am | Articles | CommentsBioConvergence LLC is a contract services firm specializing in product development services including: analytical, process and formulation development for small and large molecules.
Contract Formulation Company Profile - Azopharma
March 3, 2009 3:47 am | Articles | CommentsAzopharma Product Development Group provides comprehensive drug development services from discovery to commercialization.
Contract Formulation Company Profile - Analytical Research Laboratories
March 3, 2009 3:41 am | Articles | CommentsARL supports new drug development during the early stage of drug discovery and development .
Contract Formulation Company Profile - Almac
March 3, 2009 3:33 am | Articles | CommentsAlmac offers an extensive range of drug development services from biomarker discovery and validation; genomic services; chemical development and supply of API; pharmaceutical development, manufacture, preparation, distribution, and management of clinical supplies (including IVRS/EDC/ePRO); through to commercial manufacture and packaging of pharmaceutical product.
The Pittsburgh Conference Announces the 2009 PCMNCG Awardees
March 3, 2009 3:13 am | News | CommentsThe Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy is pleased to announce the 2009 recipients of the Pittsburgh Conference Memorial National College Grants.
Scanning Electron Microscope
March 3, 2009 3:03 am | Product Releases | CommentsFEI’s Magellan extreme high-resolution scanning electron microscope (XHR SEM) allows scientists and engineers to see 3D surface images at many different angles.
Chemical Imaging System
March 3, 2009 3:00 am | Product Releases | CommentsChemImage is set to help generic drug makers achieve bioequivalence for nasal spray suspensions and inhalation products by providing an accurate way to determine drug particle size distribution in a drug product.
Newly Discovered Gene Plays Role in Cancer
March 2, 2009 6:21 am | News | CommentsScientists at Karolinska Institutet in Sweden have shown that a previously unknown gene, Wrap53, controls the activity of the gene p53.
Vegetable-based Drug Could Inhibit Melanoma
March 2, 2009 4:48 am | News | CommentsCompounds extracted from green vegetables such as broccoli and cabbage, when combined with selenium, could be a potent drug against melanoma, according to cancer researchers.
Wyeth Giving Top Execs $22M in Pfizer Deal
March 2, 2009 4:21 am | by Linda A. Johnson, AP Business Writer | News | CommentsTop Wyeth executives will get multimillion-dollar cash payouts related to the pharmaceutical company's pending acquisition by Pfizer Inc., according to a regulatory filing.
Documents Show AstraZeneca Knew of Seroquel Risks
March 2, 2009 4:07 am | by Linda A. Johnson, AP Business Writer | News | CommentsInternal AstraZeneca reports and e-mails written by company officials show they knew a decade ago that their psychiatric drug Seroquel caused diabetes and major weight gain, said lawyers for plaintiffs suing the company.
Big Job Awaits New HHS Chief
March 2, 2009 3:55 am | by Ricardo Alonzo-Zaldivar, Associated Press Writer | News | CommentsAs President Barack Obama's health secretary, Kansas Governor Kathleen Sebelius immediately will face a host of difficult policy issues including safety lapses at the FDA.
